NYSE American - Delayed Quote USD

AIM ImmunoTech Inc. (AIM)

0.4065 -0.0235 (-5.47%)
At close: April 25 at 3:59 PM EDT
0.4154 +0.01 (+2.19%)
After hours: April 25 at 7:49 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Thomas K. Equels Esq., J.D., M.S. Executive Vice Chairman, CEO & President 953.19k -- 1953
Mr. Robert Dickey IV, M.B.A. Chief Financial Officer 64.48k -- 1956
Mr. Peter W. Rodino III, Esq., J.D. COO, Executive Director of Governmental Relations, General Counsel & Secretary 484.94k -- 1951
Ann Marie E. Coverly Director of Administration & Human Resources and Deputy Investor Relations Coordinator -- -- --
Dr. Carol A. Smith Chief Manufacturing Officer & Deputy Chief Scientific Officer 170.77k -- 1951
Dr. Christopher McAleer Ph.D. Scientific Officer -- -- --
Dr. Ralph Christopher Cavalli Ph.D. Vice President of QC & Manufacturing 234.79k -- 1958

AIM ImmunoTech Inc.

2117 SW Highway 484
Ocala, FL 34473
United States
352 448 7797 https://aimimmuno.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
26

Description

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

Corporate Governance

AIM ImmunoTech Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 13, 2024 - May 17, 2024
AIM ImmunoTech Inc. Earnings Call

Related Tickers

ACET Adicet Bio, Inc.
1.8100
-3.47%
 
ALZN Alzamend Neuro, Inc.
0.7000
-1.30%
 
GRI GRI Bio, Inc.
0.4302
-1.65%
 
MNPR Monopar Therapeutics Inc.
0.6275
-4.49%
 
MTEM Molecular Templates, Inc.
1.6000
-2.44%
 
QLGN Qualigen Therapeutics, Inc.
0.2970
-3.85%
 
VAXX Vaxxinity, Inc.
0.1214
-8.45%
 
APRE Aprea Therapeutics, Inc.
5.35
+5.52%
 
KPRX Kiora Pharmaceuticals, Inc.
0.4800
-5.10%
 
BRTX BioRestorative Therapies, Inc.
1.2300
-3.15%